Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Insulin release from pancreatic beta cells is a tightly regulated physiological process essential for maintaining blood glucose homeostasis. Beta cells, located in the islets of Langerhans within the pancreas, are the sole source of insulin synthesis and secretion in mammals. Insulin is released primarily in response to elevated blood glucose levels but can also be modulated by other nutrients and hormones. The process involves glucose sensing, ATP production, K_ATP channel closure, membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Impaired beta cell function is central to the pathogenesis of both type 1 and type 2 diabetes.
Sulfonylureas stimulate insulin release by closing K_ATP channels. GLP‑1 receptor agonists enhance glucose-stimulated insulin secretion.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin Release from Pancreatic Beta Cell (N/A).